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ABSTRACT
p300 regulates the transcriptional activity of a
variety of transcription factors by forming an
activation complex and/or promoting histone acet-
ylation. Here, we show a unique characteristic of
orphan receptor TR3 in negatively regulating the
function of p300. TR3 was found to interact with
p300 and inhibited the acetylation of transcription
factors induced by p300, resulting in the repression
of their transcriptional activity. Further analysis
revealed that both a conserved transcriptional
adapter motif (TRAM) in p300 and a specific
sequence FLELFIL in TR3 were critical for their
interaction. TR3 binding completely covered the
histone acetyltransferase (HAT) domain of p300 and
resulted in suppression of the HAT activity, as the
p300-induced histone H3 acetylation and transcrip-
tion were inhibited with the presence TR3.
Furthermore, an agonist of TR3, a natural octaketide
isolated from Dothiorella sp. HTF3 of an endophyt-
ical fungus, was shown to be a potent compound for
inhibiting p300 HAT activity (IC50 = 1.5 kg/ml) in vivo.
More importantly, this agonist could repress the
transcriptional activity of transcription factors, and
proliferation of cancer cells. Taken together, our
results not only delineate a novel transcriptional
repressor function for TR3, but also reveal its
modulation on p300 HAT activity as the underlying
mechanism.
INTRODUCTION
p300 and its closely related protein CBP are thought to
play a fundamental role in a variety of signal transduction
pathways (1–3). They function in these pathways by
acetylating multiple target proteins, including transcrip-
tion factors such as p53 (4), NF-kB (5) and b-catenin (6),
and nuclear receptors such as ER (7), AR (8) and GR (9).
p300 and CBP are also histone acetyltransferases (HATs)
(10,11) and can modulate the chromatin structure via
acetylation of histones, which facilitates the interaction of
histones with DNA. In addition, they can act as a bridge
between transcription factors and the basal transcription
machinery (12) to enhance the transcription activation.
Nuclear orphan receptor TR3 (also termed as Nur77
and NGFI-B) is a transcription factor that plays key roles
in apoptosis and cell proliferation at both transcriptional
and post-transcriptional levels (13). TR3 functions in the
nucleus or in the mitochondria through interaction with
distinct proteins. For example, by forming a heterodimer
with retinoid X receptor a (RXRa), TR3 binds to the
retinoic acid response element (RARE) of the retinoic acid
receptor b (RARb) promoter in the presence of RXR
ligand (14,15). Once bound to DNA, the TR3/RXRa
complex promotes RARb expression, which is critical for
apoptosis induction (16,17). In addition, apoptotic agents
can induce nucleocytoplasmic shuttling of TR3. The
translocation of TR3 to mitochondria strongly promotes
apoptosis in variety of cancer cell lines (18–20). Therefore,
depending on diﬀerent cell context and stimuli, TR3 may
employ diﬀerent mechanisms to function.
Several studies have demonstrated that the activities
of p300 and CBP can be modulated by their interacting
partners. The ﬁrst example is the viral oncoprotein E1A
that can inhibit p300 and CBP acetyltransferase activities
at high concentrations (21–23). Further study revealed
that E1A inhibits nucleosomal histone modiﬁcation by the
PCAF complex and blocks p53 acetylation (21). Similar
inhibition in p53 transcriptional activity through regula-
tion of p300/CBP activity has also been observed in
human papillomavirus E6 oncoprotein (24). Another
example is vIRF, a viral IFN regulatory factor encoded
by the K9 gene of Kaposi’s sarcoma-associated herpes-
virus. vIRF inhibits p300 HAT activity by direct interac-
tion, resulting in hypoacetylation of nucleosomal histones
and perturbation of cytokine gene expression (25). On the
other hand, some cellular proteins with inhibitory
activities on p300 and CBP have also been identiﬁed,
such as Twist and the E1A-like inhibitor of diﬀerentiation
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(EID-1) (23,26,27). Twist interacts with the HAT domains
and inhibits acetyltransferase activities of p300 and PCAF
(23). E1A mimics the eﬀect of Twist in inhibiting the p300
HAT activity (23). The HOX homeodomain proteins,
acting as master developmental regulators, also inhibit
CBP HAT activity and thus function as repressors of gene
transcription (28). These sets of evidence strongly suggest
that other cellular factors with similar regulatory activities
on P300 and CBP may exist.
More recently, we have found that p300-induced p53
acetylation can be dramatically suppressed by TR3 at
the transcriptional level (29). By blocking the acetylation,
TR3 down-regulates p53 transcriptional activity and lead
to a decrease on the transcription level of MDM2 (29).
Similarly, TR3 also signiﬁcantly inhibits the p300-induced
RXRa acetylation, resulting in the disassociation of
RXRa from DNA and the translocation of RXRa with
TR3 from the nucleus to cytoplasm upon TPA stimulation
(30). These results give rise to interesting questions: is that
a unique characteristic of TR3 to negatively regulate
transcription factors that can be acetylated by p300? Does
TR3 regulate p300 acetyltransferase activity? In this study,
we attempted to uncover the molecular mechanism by
which TR3 controls the activity of p300-acetylated
transcription factors. We ﬁrst demonstrated that TR3
negatively regulates the acetylation and transcriptional
activity of many p300-regulated transcription factors.
Further analysis revealed that a physical interaction
between TR3 and p300, which requires the recognition
of a speciﬁc sequence (FLELFIL) located in the ligand-
binding domain of TR3 by the transcriptional adapter
motif (TRAM) of p300, is critical for the inhibitory eﬀect
of TR3 on p300. Importantly, binding of TR3 inhibits the
HAT activity of p300, as the p300-induced histone H3
acetylation and transcription were repressed by the
presence of TR3. Finally, we showed that an agonist of
TR3 has a strong inhibitory eﬀect on p300 HAT activity
(IC50=1.5mg/ml), by which the proliferation of breast
cancer cells was inhibited. Therefore, repression of p300
function by TR3 may represent a unique pathway for
regulating the activity of a subset of transcription factors
that can be acetylated by p300.
MATERIALS AND METHODS
Cell lines and transfection
Human embryonic kidney (HEK) 293T, cervical cancer
HeLa and breast cancer MCF-7 cell lines were purchased
from ATCC. They were maintained in Dulbecco’s
modiﬁed Eagle medium supplemented with 10% fetal
calf serum, 100 mg/ml penicillin and 100 mg/ml streptomy-
cin. Transfection was performed using calcium phosphate
precipitation method for 293T cells, and liposomal
transfection reagent (Roche, Indianapolis, IN, USA,
Fugene 6) for HeLa and MCF-7 cells.
Acetylation assay
Cell lysates were extracted in cell lysis buﬀer [20mmol/l
HEPES (pH 7.5), 0.1mol/l KCl, 0.4mmol/l EDTA,
0.2% NP-40, 10mmol/l b-mercaptoethanol, 0.1mmol/l
phenylmethylsulfonyl ﬂuoride, 10 mg of pepstatin per ml,
1 mg of Na3VO4 per ml] and immunoprecipitated with
antibodies against various tags, including GFP (Santa
Cruz, CA, USA) and Myc (Santa Cruz). The immuno-
precipitates were then separated by SDS–PAGE and
blotted with speciﬁc anti-acetyl-lysine antibody (Upstate,
Lake Placid, NY).
Co-immunoprecipitation and western blotting
Cells were transfected with various plasmids as required
and harvested at 36 h post-transfection. Cell lysate
preparation, immunoprecipitation and western blotting
were performed as described previously (29). Brieﬂy, cell
lysates were incubated with the appropriate antibody for
1 h, and subsequently incubated with protein A-Sepharose
beads for 1 h. The protein–antibody complexes that were
recovered on beads were subjected to western blot analysis
using diﬀerent antibodies as required after separation
by SDS–PAGE. The immunoreactive products were
then detected by using Enhanced chemiluminescence kit
(Amersham, NJ, USA). Both p300 and TR3 antibodies
were purchased from Santa Cruz.
Luciferase reporter assay
Cells were transfected with diﬀerent luciferase reporter
genes, b-galactosidase (b-gal) and other diﬀerent expres-
sion vectors as required. After transfection, luciferase
activity was normalized for transfection eﬃciency using
corresponding b-gal activity. The ratios of luciferase/b-gal
activity were used as indicators for transcriptional activity
of diﬀerent promoters.
GST pull-down assay
Various DNA coding sequences were generated by PCR
and cloned into the expression vector pGEX-4T-1. The
resulting plasmids were transformed into BL-21 bacterial
cells and induced to express fusion proteins at 378C. GST-
fusion proteins were puriﬁed using glutathione-agarose
beads. For TR3 binding, the GST-tagged TR3 protein
bound to beads were incubated with 500 ml of whole cell
lysate from 293T cells that transfected with HA-p300.
After incubation for 5–6 h, unbound proteins were
removed by washing with lysis buﬀer. Bound proteins
were eluted by boiling for 10min in 1 loading buﬀer,
resolved by SDS–PAGE and examined by immunoblot
analysis with anti-HA antibody to detect p300. GST alone
was used as a control.
HAT activity assay
Cells were transfected with diﬀerent expression vectors,
including HA-p300, Flag-TR3 or siRNA-TR3 (The DNA
target sequence for silencing TR3, CAGTCC
AGCCATGCTCCTC, was constructed in the pSuper
vector) as required. After transfection, cell lysates were
prepared and immunoprecipitated with anti-HA or anti-
Flag antibody. The in vitro HAT activity was assayed by
measuring the histone acetylated by p300 as described
elsewhere (31). Typically, the 25 ml reaction mixture
containing immunoprecipitated lysates, 10 mg histone
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and 10 mM acetyl-coenzyme A in HAT assay buﬀer
(50mM Tris–HCl, pH 8.0, 10% glycerol, 0.1mM EDTA
and 1mM dithiothreitol) was incubated at 308C for
30min, and then subjected to SDS–PAGE for protein
separation. Acetylated histone was analyzed by western
blotting using anti-acetylated histone H3 antibody (Sigma,
St. Louis, MO, USA).
For in vivo HAT activity, cells were treated with TR3
agonist at diﬀerent concentration as indicated for 5 h
before harvest. The cell lysates were directly subjected to
analyze acetylated histone as described above.
BrdU assay
Cells were transfected with relative expression vectors
as indicated, then treated with or without TR3 agonist.
After incubating with 5-bromo-20-deoxyuridine (5-BrdU,
20 mM) (Sigma) for 2 h, cells were ﬁxed with 4%
paraformaldehyde for 30min at 48C, and then incubated
with saponin (0.1%) for another 10min. The cells were
washed twice with PBS containing 0.1% saponin, and
resuspended in PBS containing 30 mg of DNase I. After
incubation with anti-BrdU antibody (Santa Cruz) for 1 h,
cells were given two PBS washes and then incubated with
PE-linked anti-mouse antibody (Santa Cruz). Finally, cells
were analyzed by ﬂow cytometer (Backman Coulter,
Fullerton, CA, USA).
Isolation of an agonist of TR3
The endophytical fungal strain Dothiorella sp. HTF3 was
isolated from mangrove tree and cultured in liquid potato
dextrose broth media. A bank of natural products
was puriﬁed from the mycelia of the endophytic fungi
and subjected to the TR3 agonist/antagonist screening
designed by our group. A compound was found to
function as a TR3 agonist. Structural analysis by nuclear
magnetic resonance (NMR) revealed that this compound
is an octaketide. Our unpublished studies demonstrated
that this compound binds to TR3 ligand-binding domain
to induce TR3 mRNA and protein expression, and
activate its transcriptional activity (Zhan et al., unpub-
lished data).
RESULTS
TR3 negatively regulates p300-acetylated
transcriptional factors
Recently, we found that TR3 negatively regulates the
transcriptional activity of p53 (29) and retinoid X
receptor (RXRa) (30) through the p300-dependent
acetylation pathway. These results strongly suggest
that TR3 may also inhibit the activity of other p300-
acetylated transcription factors. To test this possibility,
we ﬁrst examined the eﬀect of TR3 on the p300-induced
acetylation of a broad spectrum of substrates. When
whole-cell lysates were analyzed by western blotting
with speciﬁc anti-acetyl-lysine antibody, a dramatic
increase in total protein acetylation was observed upon
the expression of p300 (Figure 1A, lane 2). As we
expected, coexpression of TR3 with p300 led to a
decrease in the total protein acetylation level in a dose-
dependent manner (Figure 1A). We found that TR3
neither interfered with p300 expression (Figure 1A), nor
was acetylated by p300 (Figure 1B). Clearly, TR3 has a
unique characteristic in inhibiting p300-induced acetyla-
tion of numerous cellular proteins.
We then chose several transcription factors and nuclear
factors, which have been approved to be acetylated by
p300, to analyze the eﬀect of TR3 on their transcriptional
activity. Consistent with previous reports, estrogen recep-
tor (ER), glucocorticoid receptor (GR), androgen receptor
(AR), p65 and b-catenin (5–9) were all acetylated by p300
(Figure 1C). Intriguingly, TR3 has a dramatically inhibi-
tory eﬀect on the acetylation of these factors. When TR3
was introduced into 293T cells that had been transfected
with p300 and these factors respectively, the p300-induced
acetylation of each factor was signiﬁcantly attenuated
(Figure 1C). We further tested whether TR3 could
modulate p300-dependent transcriptional activity of the
transcription factors. For this purpose, diﬀerent reporter
genes linked with luciferase, including ER response
element (ERE), steroid hormone responsive elements in
the mouse mammary tumor virus (MMTV-Luc), Tcf4
reporter gene (Top-ﬂash) and NF-kB responsive elements
(HIV-NF-kB) and their corresponding transcription fac-
tors, together with p300 and TR3, were transfected into
293T cells. The result showed that p300 exerted clear
activation on transcriptional activities of these transcrip-
tion factors (Figure 1D, bar 3). However, coexpression of
TR3 rendered p300 almost completely incapable of
activating transcriptional activity of these factors in a
dose-dependent manner (Figure 1D), which correlates well
with the result shown in Figure 1C. Together, these results
demonstrate that TR3 indeed possesses a unique char-
acteristic to repress the activity of transcription factors that
are commonly regulated by p300 acetylation.
TR3 physically interacts with p300
The ﬁnding that TR3 regulates the transcriptional activity
of p300-acetylated transcription factors promoted us to
determine whether TR3 physically interacts with p300 in
cells. To test this possibility, Myc-TR3 and HA-p300 were
coexpressed in 293T cells, followed by reciprocal immuno-
precipitation with anti-Myc for TR3 and anti-HA for p300.
Western blotting showed that TR3 was readily detected
when p300 was immunoprecipitated (upper panel); simi-
larly, p300 was also detected in the immunoprecipitates of
TR3 (lower panel), suggesting TR3 interaction with p300 at
exogenous level. We carried out another parallel experi-
ment to test whether endogenous TR3 and p300 could
interact with each other using lysates of untransfected
HeLa cells. The results showed that p300 could be detected
in the immunoprecipitates of TR3 (Figure 2B), indicating
the association of TR3 with p300 at the endogenous level.
GST pull-down experiment further demonstrated that
GST-TR3 can bind HA-p300 that was transfected into
293T cells and immunoblotted by HA antibody
(Figure 2C). Together, these results suggest that TR3 has
a physical interaction with p300 in the cells.
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Figure 1. TR3 represses transcriptional activities of transcription factors through inhibiting p300-induced acetylation. (A) TR3 inhibits the
acetylation of a broad spectrum of substrates. HA-p300, with increasing amount of Flag-TR3, was transfected into 293T cells. Lysates were prepared
from transfected cells and subjected to western blotting. The acetylated proteins were detected by anti-acetylation-speciﬁc antibody. The levels of
Flag-TR3 and HA-p300 were shown by anti-Flag and anti-HA antibodies, respectively. Tubulin was used to indicate the similar loading of proteins
in each lane. (B) TR3 cannot be acetylated by p300. GFP-TR3 and HA-p300 were transfected into 293T cells. Cell lysates were prepared and GFP-
TR3 was immunoprecipitated with anti-GFP antibody. The precipitated proteins were then subjected to western blotting with acetylation-speciﬁc
antibody. p53, which is known to be acetylated by p300, was used as a positive control. GFP-TR3 and GFP-p53 were also detected by western
blotting with anti-GFP antibody. (C) TR3 attenuates p300-induced acetylation of various transcription factors. HA-p300 and Flag-TR3 together
with diﬀerent tagged transcription factors as indicated were transfected into 293T cells. Acetylation for each transcription factor was determined as
described above. The expression levels of various transcription factors were indicated by western blotting with antibodies corresponding to diﬀerent
tags. (D) TR3 represses p300-induced transcriptional activity of various transcription factors. Diﬀerent transcription factors and their corresponding
reporter genes, together with p300, b-gal expression vector and increasing amount of TR3, were transfected into 293T cells. Reporter gene activity
was determined and normalized in relation to the cotransfected b-gal activity. The bars represent the average  mean from three independent
experiments.
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We next went on to map the regions within TR3 and
p300 that are responsible for their interaction. Diﬀerent
truncation mutants of p300 were constructed as indicated
(Figure 2D, upper panel) and tested for interaction with
TR3 by co-immunoprecipitation (Co-IP) experiment.
When co-expressed with the full-length TR3 in 293T cells,
the p300 mutant p300/M2, but not p300/N1 and p300/C1,
retained the ability to interact with TR3 (Figure 2D),
indicating that the region of amino acids (aa) 1039–1874 is
responsible for p300 to interact with TR3. Furthermore, we
found that p300/N2 and p300/M1 also interacted with TR3
(Figure 2D), suggesting that the cysteine-histidine-rich
region 2 (CH2) of p300 is suﬃcient for TR3 binding, but
other domains, such as the cysteine-histidine-rich region
CH3, may also contribute to the interaction.
Diﬀerent deletion mutants of TR3 were also generated
(Figure 2E, upper panel) to test the interaction with p300.
As shown in Figure 2E, TR3 deletion mutant D4 but not
D3 showed the ability to interact with p300, suggesting
that the N-terminal region of TR3 is not required for p300
binding. Further analysis revealed that deletion mutants
TR3/D1, TR3/D5 and TR3/D6 all interacted with p300,
but TR3/D2 failed to do so (Figure 2E). These results
suggest that at least two regions, the DNA-binding
domain (DBD) and the region of aa 439–521 of TR3,
are capable of binding to p300.
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Figure 2. Mapping of domains responsible for the interaction between TR3 and p300. (A) TR3 and p300 form a complex in 293T cells. Myc-TR3
and HA-p300 were transfected either alone or together into cells. Cell lysates were prepared and then subjected to immunoprecipitation, followed by
western blotting analysis with anti-Myc or anti-HA antibodies as indicated. (B) Interaction of TR3 with p300 in the absence or presence of TR3
agonist in HeLa cells. Cell lysates were immunoprecipitated with anti-TR3 antibody and control IgG, respectively, followed by western blotting with
anti-p300 antibody. (C) Pull-down of p300 by TR3. GST-TR3 was expressed in Escherichia coli cells and puriﬁed as described in Materials and
Methods section. The beads-bound GST-TR3 was incubated with the lysate of 293T cells transfected with HA-p300. HA-p300 was indicated with
anti-HA antibody. GST was used as a negative control. Lower panel indicated the amount of GST and GST-TR3 used in the assay.
(D) Determination of TR3-binding sites in p300. Schematic diagrams depicting diﬀerent p300 truncation mutants are shown in upper panel. Full-
length Myc-TR3 and diﬀerent HA-p300 mutants were transfected into 293T cells as indicated. Cell lysates were immunoprecipitated with anti-Myc
antibody. The immunoprecipitates and cell lysates were analyzed by western blotting with anti-HA and anti-Myc antibodies for p300 and TR3
proteins, respectively. (E) Determination of p300-binding sites in TR3. Schematic diagrams (upper panel) depict diﬀerent truncation mutants of TR3.
Full-length HA-p300 and diﬀerent Flag-TR3 mutants were transfected into 293T cells as indicated. Cell lysates were immunoprecipitated with anti-
HA antibody. The immunoprecipitates and cell lysates were analyzed by western blotting with anti-HA and anti-Myc antibodies for p300 and TR3
proteins, respectively.
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TR3 binding inhibits the HAT activity of p300
The HAT domain of p300 is located at the middle region
of the protein that shows a physical interaction with TR3
(Figure 2D), indicating that the HAT activity of p300 may
also be impaired by TR3 binding. We therefore assayed
the p300 HAT activity by utilizing previously described
systems (28,32). We ﬁrst examined the acetylation level of
histone H3, as Histone H3 acetylation is usually used to
reﬂect p300 HAT activity (25,32). In 293T cells that were
cotransfected with TR3 and p300, TR3 indeed exhibited a
strong inhibition on p300 HAT activity, as 74% of such
activity had lost when 2 mg of TR3 was introduced
(Figure 3A). We further examined the eﬀect of diﬀerent
TR3 deletion mutants on the HAT activity of p300.
Similar to full-length TR3, TR3/D1, TR3/D4 and
TR3/D6 could eﬃciently inhibit p300 HAT activity,
reaching to 60% inhibition (Figure 3B). A common
feature for these deletion mutants is that they all contain
the region of aa 439–521 that interacts with p300
(Figure 2E). In contrast, TR3/D2, TR3/D3 and TR3/D5
showed no eﬀect on p300 HAT activity (the activity was
remained at almost 100% in all the tested mutants except
TR3/D5) (Figure 3B), even though TR3/D5 could interact
with p300 via the DBD (Figure 2E). Thus, these results
suggest that the region of aa 439–521, rather than the
DBD, is essential for TR3 to inhibit p300 HAT activity.
Since p300 HAT activity is thought to stimulate
transcription by acetylating Histones (25,33), we next
examined whether the repression of p300 acetyltransferase
activity by TR3 will result in inhibition of p300-activated
gene transcription. For this end, a truncated p300
fragment containing the HAT domain (aa 1039–1874)
was fused to Gal4 protein (Gal4-p300/HAT), and
cotransfected into 293T cells together with a reporter
construct containing the luciferase gene controlled by ﬁve
GAL4 response elements (pGAL4) (34). As shown in
Figure 3C, Gal4-p300/HAT obviously activated the
transcription of the reporter gene. However, cotransfec-
tion of TR3 abrogated the eﬀect of Gal4-p300/HAT in a
dose-dependent manner (Figure 3C), suggesting that
p300-mediated gene transcription is regulated by TR3.
In the parallel experiment, a decrease in transcription
activation was observed when TR3 mutants D1, D4 and
D6 but not D2, D3 and D5 were used (Figure 3D).
Considering the varied interactions between p300 and
TR3 mutants (Figure 2E), it is likely that TR3 binding to
p300 inhibits both p300 HAT activities and activation of
transcription.
TRAM in p300 and FLELFIL sequence in TR3 are critical
to modulate HAT activity
Interestingly, when TR3 was cotransfected into 293T cells
with either p300/M1 or p300/M2, both of which retain the
p300 HAT activity fully, it only inhibited the HAT activity
of p300/M2 with 78% approximately, but not that of
p300/M1 (the approximate inhibition was 6%)
(Figure 4A). Compared to p300/M1, p300/M2 contains
extra sequences in which a motif (RKTNGGCPICKQ)
called TRAM can be found (Figure 2D). TRAM has been
shown to be conserved in all members of the CBP/p300
family of proteins and is responsible for speciﬁc recogni-
tion of target proteins (35). In p300, TRAM is located
within the CH3 domain just after the HAT domain
(36,37). Our result clearly demonstrated that TRAM plays
an important role in mediating the inhibition of TR3 on
p300 HAT activity.
It has been shown that CBP/p300 can speciﬁcally
recognize a small sequence (FXE/DXXXL) on E1A,
p53, E2F and TFIIB through its TRAM (35).
Interestingly, we found that TR3 contains a FLELFIL
sequence (aa 443–449), which is similar to the
FXE/DXXXL motif, within the region of TR3/D6
(Figure 2E). To determine whether this sequence facil-
itates p300 TRAM recognition, we constructed a new
mutant (TR3/D7) based on the structure of TR3/D6
mutant, where the Phe (F) in aa 443 and the Glu (E) in aa
445 were replaced with Ala (A) simultaneously
(Figure 2E). When this mutant was cotransfected into
293T cells with p300, it failed to bind p300 (Figure 4B),
and exhibited no inhibitory eﬀect on p300 HAT activity
A
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Figure 3. TR3 inhibits p300 HAT activity. (A) Eﬀect of TR3 on p300
HAT activity. HA-p300 and increasing amount of Falg-TR3 were
transfected into 293T cells. Cell lysates were prepared and HA-p300
was immunoprecipitated with anti-HA antibody. The precipitates were
then incubated with histone (10 mg) and Lys-CoA (10 mM) at 308C for
30min. The reaction products were subjected to western blotting with
anti-Ack-H3 antibody to show the HAT activity. The levels of TR3,
p300 and histone H3 were indicated by western blotting with anti-Flag, -HA
and -histone antibodies. The percentage of Ack-H3 inhibition was
calculated by determining the Ack-H3 protein amount of individual
bands using densitometry. (B) Diﬀerent TR3 mutants impair p300
HAT activity. Flag-TR3 mutants together with full-length HA-p300,
were transfected into 293T cells. The HAT activity of p300 was
determined as described above. Ack-H3 inhibition was determined by
using densitometry. (C and D) TR3 inhibits p300 HAT-mediated
transcription. Gal4-p300/HAT, together with a luciferase reporter gene
pGAL4 and increasing amount of TR3 (C) or TR3 deletion mutants
(D), was cotransfected into 293T cells. Reporter gene activity was
determined as described in Figure 1D. The bars represent the average
 mean from three independent experiments.
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(the inhibitory rate was only 1%), but TR3/D6 exerted
higher inhibition (68%) on HAT activity (Figure 4C),
suggesting that the FLELFIL sequence is critical for TR3
to inhibit the HAT activity of p300. To exclude out the
possibility that such inhibitory eﬀect of TR3/D7 is due to
the deleted sequences of TR3 instead of the mutated
sequence, we introduced the same mutations into full-
length TR3 to create TR3/D8 (Figure 2E). Although TR3/
D8 still interacted with p300 (probably through its DBD)
(Figure 4B), it could not repress the HAT activity of p300
anymore (Figure 4C, the inhibitory rate was only 3%) as
compared to the full-length TR3 (Figure 3A, the
inhibitory rate was 74%). This result further conﬁrmed
that the FLELFIL sequence is necessary to ensure the
suppression of TR3 on p300 HAT activity.
As p300 HAT activity is associated with its ability to
activate transcription factors (4–8,38), we further deter-
mined whether TR3 modulation on p300 HAT activity
impairs the transcriptional activity of various transcrip-
tion factors, and whether this regulation requires the
FLELFIL sequence of TR3. When diﬀerent TR3 mutants
were tested, we found that TR3/D1, TR3/D4 and TR3/D6
repressed the reporter gene activities of all the transcrip-
tion factors induced by p300 as eﬀectively as the full-
length TR3 (Figure 4D). In contrast, mutants lacking the
FLELFIL sequence, such as TR3/D2, TR3/D3 and
TR3/D5, did not show any inhibition on activities of
reporter genes for all transcription factors (Figure 4D).
Similar result was observed when the TR3/D7 and
TR3/D8 mutants, of which the FLELFIL sequence had
been mutated, was used (Figure 4D). Taken together,
these results all suggest that TR3 may inhibit the
transcriptional activity of transcription factors through
repression of p300 HAT activity.
Roles of a TR3 agonist in regulating p300 functions
Recently, we screened a bank of the natural products from
fungi and found an agonist of TR3. This agonist
speciﬁcally activated TR3 transactivation through target-
ing to the TR3 ligand-binding domain (Zhan et al.,
unpublished data), and promoted the expression of TR3
mRNA and protein (Figure 5A–C). Co-IP assay showed
that agonist could enhance the TR3–p300 interaction at
endogenous level (Figure 2B). If TR3 is a genuine factor
for inhibition of p300 HAT activity, it is expected that this
agonist would also have such an inhibitory eﬀect on p300
HAT activity as well as the transcriptional activity of
p300-induced transcription factors. We ﬁrst analyzed the
role of TR3 agonist in p300-dependent HAT activity. As
shown in Figure 5B, agonist did not impair the expression
levels of p300 and Histone H3, but indeed down-regulated
p300 HAT activity in a concentration-dependent manner;
meanwhile, the expression levels of endogenous TR3 were
up-regulated with increase of agonist dose (Figure 5B, left
panels). The IC50 (inhibitory concentration of agonist for
50% reduction of the HAT activity) was 2.2 mg/ml in the
in vitro assay and 1.5 mg/ml in the in vivo assay (Figure 5B,
right panels). To conﬁrm that such inhibition was directly
mediated by TR3, a siRNA against TR3 was introduced
into cells to inhibit endogenous TR3 expression. When
Figure 4. Eﬀects of diﬀerent mutants of p300 and TR3 on regulation of
HAT activity and transcriptional activity of transcription factors. (A and
C) Diﬀerent p300 or TR3 mutants impair TR3 inhibition on p300 HAT
activity. Diﬀerent Flag-p300 mutants (A) or Myc-TR3 mutants (C),
together with full length of Myc-TR3 (A) or HA-p300 (C), were
transfected into 293T cells. The HAT activity of p300 was determined
as described above. The percentage of Ack-H3 inhibition was calculated
by using densitometry. (B) Interaction of p300 with diﬀerent TR3
mutants. HA-p300 and Myc-TR3 mutants were transfected into 293T
cells. Cell lysates were prepared and then subjected to Co-IP/western
blotting as described in Figure 2A. (D) Eﬀect of diﬀerent TR3 deletion
mutants on transcriptional activity of various transcription factors. p300,
together with diﬀerent TR3 mutants, transcription factors and reporter
genes, was cotransfected into 293T cells. The transcriptional activity was
determined as described in Figure 1D.
7354 Nucleic Acids Research, 2007, Vol. 35, No. 21
AB
D
E
C
Figure 5. Inhibition of TR3 agonist on p300 HAT activity. (A) Agonist up-regulates TR3 mRNA expression levels. HeLa cells were treated
with diﬀerent concentrations of agonist as indicated for 5 h, and total RNA was then prepared. The levels of TR3 mRNA were determined by
RT-PCR. Representatives of at least two independent experiments with similar results are shown. The level of TR3 mRNA induced by agonist was
determined by using densitometry. (B) Eﬀect of TR3 agonist on p300 HAT activity. 293T cells transfected with HA-p300 (upper panel) or HeLa
cells (lower panel) were treated with diﬀerent concentrations of agonist (1–4 mg) as indicated for 5 h, then the p300 HAT activity was determined
as described in Figure 3A. The expression levels of HA-p300, endogenous TR3 and histone H3 were determined by western blotting with anti-HA,
-TR3 and -histone H3 antibody, respectively. The level of TR3 protein induced by agonist was determined by using densitometry. Right panels
indicated IC50 values that were calculated by determining the concentration of agonist needed to promote 50% inhibition of agonist activity.
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endogenous TR3 was inhibited by its RNA interfere, the
inhibitory eﬀect of agonist on p300 HAT activity was not
detected (Figure 5C). TR3 agonist also repressed p300-
activated transcription of GAL4 response elements linked
luciferase gene, and such repression could be diminished
by siRNA-TR3 (Figure 5D). In addition, while introduc-
tion of p300 into 293T cells activated the expression of
luciferase reporter gene for a series of transcription factors
(Figure 5E, lane 2), agonist exerted an obvious inhibition
on reporter gene activities with a dose-dependent fashion
(Figure 5E), but failed to do so in the presence of siRNA-
TR3 (Figure 5E, lane 6). Clearly, the repression of p300
HAT activity and activities of reporter genes by agonist is
mediated by TR3.
Finally, we addressed the biological signiﬁcance of TR3
agonist in DNA synthesis by performing the BrdU assay
in breast cancer cells MCF-7. As shown in Figure 5F (left
panel), transfection of AR along caused the curve right-
moved (green curve) as compared with the control (red
curve). Cotransfection of p300 with AR displayed an
obvious increase in BrdU incorporation (black curve),
consistent with the fact that p300 can acetylate AR to
enhance the growth of prostate cancer cell (8). We further
examined whether TR3 agonist has an inhibitory eﬀect on
p300-mediated and AR-dependent proliferation of MCF-
7 cells (right panel). Compared with the control (transfec-
tion of p300 and AR only) (red curve), a left-moved curve
was seen after treatment with agonist (green curve). Once
siRNA against TR3 was introduced into cells, the curve
converted from the left to right and almost overlapped
with the control (black curve). These results demonstrate
an important role of TR3 in p300-mediated cell growth.
DISCUSSION
p300 and the closely related protein CBP have been shown
to interact with a large number of transcription factors
(39). In the present study, we showed that orphan nuclear
receptor TR3 physically interacts with p300 in the cells
and consequently inhibits the HAT activity of p300.
Analysis of a structural basis for the mechanism by which
TR3 controls the p300-dependent HAT activity revealed
that the sequence FLELFIL in TR3 is required for p300
recognition, and the TRAM motif in p300 is critical for
TR3 binding to repress p300 HAT activity. Furthermore,
we demonstrated a unique characteristic of TR3 in
negative regulation of a broad range of transcription
factors that were acetylated by p300. TR3 was found to
exert its inhibitory eﬀect on the transcriptional activity of
transcription factors through repressing the p300-induced
acetylation. In addition, we used a TR3 agonist that
mimics TR3 function to verify the ﬁndings mentioned
above. The results indicated that the agonist indeed
represses transcriptional activities of transcription factors
through inhibiting p300 HAT activity, and suppresses the
DNA synthesis and the proliferation of breast cancer cells
by regulating p300. Together, our results uncover a novel
mechanism by which the orphan receptor exerts its eﬀects
on fundamental aspects of cell functions.
E1A and Twist have been shown to bind the CH3
domain of p300/CBP (23,36). Within CH3 domain there
exists a conserved 12-residue transcriptional adapter motif
named TRAM. TRAM is a hot spot to be bound by
various transcription factors, such as E1A (35) and
numerous cellular transcription factors (24,35). TRAM
functions as a transcriptional adapter to provide HAT
activity and/or to bridge the gap between transcription
factors and components of the basal transcription
machinery (4,35). In the present study, p300 could activate
transcriptional activity of various transcription factors
(Figure 1D) through the acetylation pathway (Figure 1C).
On the other hand, TR3 displayed a pronounced
preference for inhibiting p300-induced transcriptional
activity (Figure 1D). It is very likely that this unique
property of TR3 is associated with its interaction with
p300 (Figure 2). TR3 binding to TRAM of p300 resulted
in the inhibition of p300 HAT activity (Figure 4A). When
TRAM was removed, TR3 still bound to p300 at the CH2
domain (Figure 2D), but failed to inhibit the HAT activity
(Figure 4A). Therefore, TRAM is a necessary binding
target for TR3 to inhibit p300 HAT activity. Here, we
propose a possible model to illustrate how TR3 negatively
regulates p300 function (Figure 6). According to this
F
Figure 5. Continued.
(C) Eﬀect of agonist on p300 HAT activity is attenuated by siRNA-
TR3. siRNA-TR3 with p300 were transfected into 293T cells.
Transfected cells were treated with agonist (4 mg) for 5 h. The HAT
activity was determined as described in Figure 3A. (D) Eﬀect of agonist
on transcription induced by p300 HAT. Gal4-p300/HAT and a
luciferase reporter gene pGAL4, with or without siRNA-TR3, was
cotransfected into 293T cells. Transfected cells were treated with
agonist (4 mg) for 5 h. Reporter gene activity was determined as
described in Figure 1D. The bars represent the average  mean from
three independent experiments. (E) Eﬀects of agonist and siRNA-TR3
on p300-induced transcriptional activity. p300 with diﬀerent transcrip-
tion factors and reporter genes was transfected into 293T cells, and cells
were treated with agonist at diﬀerent concentration (1, 2 and 5 mM).
The transcriptional activity was determined as described in Figure 1D.
In addition, siRNA-TR3 was introduced into cells to abolish agonist
function as required. (F) TR3 agonist inhibits p300 and AR-mediated
mitogenic activity. Diﬀerent expression vectors, including HA-p300,
GFP-AR and siRNA-TR3, were transfected into breast cancer MCF-7
cells as indicated, and the transfected cells were treated with or without
agonist (4 mg) for 5 h. Cells were maintained in BrdU containing
medium for 2 h and then identiﬁed by ﬂow cytometry.
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model, TRAM is a key site for TR3 binding to p300
(Figure 6, lower right panel). Once seated on TRAM, TR3
might completely cover the region of CH3 (Figure 6,
upper panel), hence abrogates p300 HAT activity
(Figure 3B). In addition to TRAM, another key factor is
the FLELFIL sequence of TR3, as it is crucial for TRAM
recognition (Figure 6, lower left panel).
Although few signature motifs have been identiﬁed in
transcription regulators that would predict with certainly
their ability to bind to a given domain within p300/CBP,
a short sequence FXE/DXXXL has been identiﬁed in
E1A, p53 and E2F that forms speciﬁc contacts with the
TRAM motif in the CH3 domain of p300/CBP (35).
Within TR3, two p300-interacting domains were deter-
mined, one is the DBD, the other is the FLELFIL
sequence located in the ligand-binding domain
(Figure 2E). Functional analysis indicated that p300
binding by DBD of TR3 did not impair its HAT activity
(Figure 3B), whereas binding by the FLELFIL sequence
of TR3 led to p300 HAT activity lost (Figure 4C). When
the F and E in FLELFIL sequence were substituted with
A simultaneously in full-length TR3 or TR3 deletion
mutant, the eﬀect of TR3 on HAT activity was attenuated
(Figure 4C). These results suggest that TR3 inhibition on
p300 HAT activity may be dependent on an FLELFIL–
TRAM interaction. In addition, we also demonstrated
that this FLELFIL sequence is critical for TR3 to regulate
transcriptional activities of diﬀerent transcription factors
(Figure 4D). When this sequence was deleted, or two sites
in this sequence were mutated, TR3 showed no eﬀect on
the transcriptional activity of all the tested transcription
factors (Figure 4D). The physiological signiﬁcance of this
inhibition is further strengthened by the observation that
an agonist for TR3 mRNA and protein (Figure 5A–C),
inhibited transcriptional activity of various transcription
factors (Figure 5E) through repression of p300 HAT
activity (Figure 5B). Furthermore, we noted that transfec-
tion of si-TR3 did not inﬂuence p300 HAT activity
(Figure 5C, lane 2), suggesting a possibility that the
physiological levels of TR3 protein in cells are important
in setting the threshold for inhibiting p300 HAT activity.
It may be only under the circumstances that TR3 was
overexpressed (like Figure 3A, transfection of TR3) or
activated (like Figure 5B, activation of TR3 by its
agonist), TR3 would exert its inhibition on p300 HAT
activity. Taken together, these in vivo and in vitro results
support a potentially global role of TR3 in regulation of
p300 HAT activity. In future, it will be of importance to
determine whether other coactivation/HAT complexes,
such as the SAGA, CBP and TFIID complexes, as well as
other nonhistone substracts, are also sensitive to TR3
inhibition.
In fact, the interaction of TR3 with p300 has been
demonstrated previously by in vitro pull-down assay,
where 35S-radiolabeled full-length p300 interacted eﬃ-
ciently with full-length TR3 and the N-terminus of TR3,
but poorly with the C-terminus of TR3 (40). Our Co-IP
assay showed that endogenous TR3 could bind p300
(Figure 2B), and the in vivo complex formation of TR3
with p300 appeared to be TR3 agonist-dependent
(Figure 2B). However, our results revealed that the
binding to p300 occurred in both the DBD and the
C-terminus, rather than N-terminus of TR3 (Figure 2E).
This discrepancy might be derived from the diﬀerence of
assay methods and conditions: in vivo Co-IP assay versus
in vitro pull-down assay, and/or proteins extracted from
cell lysates versus GST fusion protein expressed in
bacterial and/or 35S-radiolabeled protein. Such discrep-
ancy has also been reported in KSHV vIRF targeting to
p300 (25,41,42). Alternatively, other factors, coactivators
Figure 6. A working model to illustrate the mechanism by which TR3 negatively regulates p300. TR3 binding to p300 TRAM may cover the HAT
domain and consequently inhibits HAT activity (upper panel). Point mutations of FLELFIL sequence in TR3 (lower left panel) or removal of
TRAM in p300 (lower right panel) may render TR3 fail to block the HAT domain, and therefore p300 HAT activity is not repressed.
Nucleic Acids Research, 2007, Vol. 35, No. 21 7357
or corepressors, which are likely absent in the in vitro
systems, might be involved in the formation of p300–TR3
complex in vivo.
HATs and histone deacetylases (HDAC) are thought to
be potent targets for cancer therapy. In the past years, a
number of HDAC inhibitors that can induce apoptosis in
tumor cells have been identiﬁed (43). Some of them, such
as SAHA, are already used in human trial as antineoplas-
tic drug (44). Compared with HDAC inhibitors, little is
known about HAT inhibitors. Recently, garcinol and
curcumin were found to be p300 HAT inhibitors (45,46).
They all repress p300 HAT-dependent chromatin tran-
scription, but not transcription from DNA template.
Garcinol alters global gene expression related to apopto-
sis, cell cycle, oncogene (45) and curcumin inhibits the
multiplication of HIV1. Here we showed that a TR3
agonist, a natural octaketide isolated from Dothiorella sp.
HTF3 of endophytical fungus, possesses the ability to
inhibit p300 HAT activity (Figure 5B). More importantly,
we found that TR3 could be the potential target of this
agonist, as siRNA-TR3 attenuated agonist function on
repression of p300 HAT activity and transcriptional
activity of transcription factors (Figure 5C–E). It has
been reported that in breast cancer cells, p300 binding to
AR alters expression of speciﬁc growth control genes and
promotes aberrant cellular growth in vivo (8), which is
closely associated with p300 acetylation for AR. We found
that when breast cancer cells were introduced with TR3 or
treated with agonist, the cell proliferation mediated by AR
via p300 acetylation (Figure 1C) was abolished through
blockage of DNA synthesis in the cells (Figure 5F). Thus,
our study reveals a novel function of TR3 to inhibit breast
cancer cell growth through repression of p300 HAT
activity, and indicates that the TR3 agonist may be used as
a lead compound for anticancer drug.
In summary, our study demonstrates the regulation of
p300 acetyltransferase activity by orphan receptor TR3,
and suggests that TR3 may function as a negative
regulator of a set of transcription factors whose transcrip-
tional activities are controlled by p300-mediated acetyla-
tion. We have conformed in current study that TR3 would
inhibit p300 acetylation-dependent transcription regula-
tion, since we have detected that p300-regulated Histone
acetylation was impaired by TR3 (Figure 4) or its agonist
(Figure 5B–D). However, we cannot preclude the possi-
bility that TR3 would aﬀect general transcription machin-
ery through chromatin remodeling. Histone acetylation
plays an important role in the modulation of chromatin
structure associated with signal-dependent transcriptional
activation (25,47). Previous studies have demonstrated
a dependence on acetyltransferase activity for in vivo p300
modulation of gene transcription (28,48). In this study,
we have found that GAL4-p300/HAT could activate the
transcription of reporter gene (Figure3C), and cotrans-
fected TR3, which would bind to p300 (Figure3E and F),
greatly abrogated the p300-mediated activation of tran-
scription (Figure. 3C and D). These results demonstrate
that TR3 not only diminishes the HAT activity of p300,
but also inhibits p300 HAT domain-induced transcription
activation. Therefore, TR3 may regulate the transcription
of a broader set of genes than we previously thought.
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